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Abstract: Most combination oral contraceptives contain ethinyl estradiol and a progestin. A new 
and novel oral contraceptive formulation combines estradiol valerate (E2V) with dienogest 
(DNG) in a four-phase dosing regimen. 17β-estradiol is a naturally-occurring estrogen, and 
a contraceptive pill containing such an estrogen offers potential benefits with regard to meta-
bolic side effects and adverse events. Dienogest is derived from 19-nortestosterone and exerts 
profound progestational effects on the endometrium, but it differs from other progestins in its 
class by its antiandrogenic activity. Estradiol valerate plus dienogest (E2V/DNG) is now avail-
able in a four-phasic regimen that integrates an estrogen stepdown and progestin stepup dosing 
approach along with a short two-day hormone-free interval. This regimen offers safe, reliable 
contraception and has been shown to be an effective treatment for heavy menstrual bleeding. 
Metabolic effects and adverse events appear similar to those reported with oral contraceptives 
containing ethinyl estradiol.
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Introduction
Combination oral contraceptive pills are the most commonly used form of reversible 
birth control in the US, with nearly 11 million women using them as their contraceptive 
method of choice.1 The majority of available combined oral contraceptive pills contain 
ethinyl estradiol as the estrogen component. Ethinyl estradiol is a synthetic hormone 
that efficiently delivers estrogen orally and is highly potent. Historically, there has been 
long-standing interest in developing a combined oral contraceptive pill containing estra-
diol, the most potent of the naturally occurring estrogens. The ability to do so has been 
thwarted by problems of poor oral absorption of estradiol and high rates of breakthrough 
bleeding. As such, a contraceptive pill regimen delivering estradiol instead of ethinyl 
estradiol was not successfully developed and, until recently, unavailable.2
Estradiol valerate + dienogest (E2V/DNG) is a new oral contraceptive formulation 
that provides effective contraception and satisfactory cycle control. Its novel regimen 
combines estradiol valerate (E2V), which is a prodrug that delivers estradiol, with the 
progestin, dienogest (DNG), in a four-phasic dosing scheme designed to inhibit ovula-
tion and minimize breakthrough bleeding. The 28-day formulation administers E2V 
3 mg on days 1 and 2, E2V 2 mg/DNG 2 mg on days 3–7, E2V 2 mg/DNG 3 mg on 
days 8–24, E2V 1 mg on days 25 and 26, and placebo on days 27 and 28 (Figure 1). 
This new and unique regimen offers highly effective contraception,   satisfactory 
cycle control, and has been shown to be an effective treatment for heavy menstrual 






Interest in developing a combined oral contraceptive pill 
containing estradiol rather than ethinyl estradiol began years 
ago. These efforts were based on the premise that estradiol, a 
naturally occurring estrogen, would be associated with fewer 
side effects and improved tolerability. Upon oral administra-
tion, E2V is a prodrug in which the valerate side chain of the 
molecule is rapidly cleaved to form 17β-estradiol and valeric 
acid, with the estradiol being further metabolized to estrone and 
estrone sulfate. One milligram of E2V is equivalent to 0.76 mg 
of 17β-estradiol.3 The biological effects of a 2 mg daily dose 
of E2V is similar to that of ethinyl estradiol 20 µg with regard 
to its effect on the hypothalamic–pituitary–ovarian axis and 
resulting effects on the ovaries and endometrium. However, a 
direct clinical comparison is not possible, owing to differences 
in the metabolism of the two estrogenic compounds.4
DNG is a progestin derived from 19-nortestosterone but is 
different in structure from other progestins in this class. The 
17α-ethinyl group, typical of many 19-nortestoerone proges-
tin derivatives, is replaced by a 17α-cyanomethyl group in 
DNG.5 Similar to the other agents in its class, DNG exerts a 
strong progestational effect on the endometrium. However, 
unlike other 19-nortestosterone derivatives, it is characterized 
by an overall antiandrogenic hormonal milieu.
The novel four-phasic regimen was developed to provide 
for effective inhibition of ovulation and to minimize the 
breakthrough bleeding evident with earlier iterations of 17β-
estradiol-containing and E2V-containing regimens. The dosing 
schedule provides for an estrogen stepdown simultaneously 
with progestin stepup and a short, two-day, hormone-free 
interval. The first E2V/DNG oral contraceptive regimen in the 
US was recently approved by the Food and Drug Administra-
tion in 2010, under the brand name Natazia® (Bayer, Berlin, 
Germany), and the same regimen was approved earlier in 
Europe under the brand name Qlaira® (Bayer).
The rationale for this four-phasic regimen based on 
an estrogen stepdown and progestin stepup is that early 
estrogen dominance would confer endometrial proliferation 
in the first half of the cycle and prepare the endometrium 
for a midcyclic progestin effect. Use of increasing DNG 
dosages during the cycle would provide stability to the 
endometrial stroma, especially in the middle and end stages 
of the cycle.
Mechanism of action
Oral contraceptives containing ethinyl estradiol plus proges-
tin provide for highly effective and reversible contraception. 
First-year perfect-use failure rates with the combined oral 
contraceptive pill are established as 0.3%, with typical use 
rates being 8%.6 The contraceptive action of the combined 
oral contraceptive pill results primarily from the actions of 
the hormones on the hypothalamus, pituitary, and ovaries. 
While combined oral contraceptive pills likely prevent 
pregnancy through several disparate mechanisms, their 
primary mechanism is the suppression of ovulation. The 
progestin component prevents the luteinizing hormone surge 
required for release of the ovum. It also serves to thicken 
cervical mucus and decrease tubal motility, creating a less 
facile passage for sperm. In addition, the progestin acts 
to thin the endometrium, resulting in tissue less receptive 
to   implantation. The estrogen component of the pill serves to 
promote an acceptable cycle control and bleeding profile by 
stabilizing the endometrium during the days of exogenous 
estrogen ingestion. In addition, the estrogenic component 
also serves to augment contraceptive efficacy by inhibiting 
the release of follicle-stimulating hormone from the pituitary, 
which further inhibits the development of the dominant 
  follicle. This, in turn, potentiates inhibition of the luteinizing 
hormone surge by progestin, without which ovulation and 
pregnancy cannot occur.7,8
Day of cycle 
E2V
1 mg
Placebo E2V 2 mg  E2V
3 mg
DNG 2 mg  DNG 3 mg 
28 27 25 14 8 3 2 1
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Efficacy
Similar to other combined oral contraceptive pills, E2V/DNG 
provides effective birth control. Previously, several studies of 
pills containing estradiol consistently demonstrated adequate 
contraceptive efficacy,9–13 but issues of poor cycle control and 
unfavorable bleeding profiles led to high user dissatisfaction 
and unacceptable discontinuation rates in clinical trials, and 
prevented their entry into the contraceptive marketplace.3
Two studies have evaluated inhibition of ovulation with 
E2V/DNG.14 In these dose-finding studies, four different 
dosing regimens of E2V plus DNG were assessed. All four 
regimens involved E2V stepdown and DNG stepup, but the 
doses and length of exposure of each dose varied.   Ovulation 
was assessed by transvaginal ultrasound measurement of 
ovarian follicle size and serum measurement of estradiol 
and progesterone levels, and the degree of ovulation was 
classified using Hoogland scores. Participants on each of the 
four regimens were followed for three consecutive cycles. 
These studies determined the lowest effective dose needed 
for efficacy, ie, E2V 3 mg for two days, E2V 2 mg/DNG 
2 mg for five days, E2V 2 mg/DNG 3 mg for 17 days, E2V 
1 mg for two days, then placebo for two days. No major 
safety concerns were identified with any of the regimens, 
and reported adverse events were similar to those occurring 
with use of any combined oral contraceptive pill.
A larger multicenter, open-label study evaluated healthy 
women on E2V/DNG over 20 cycles and documented low 
failure rates.3 Of 1377 women aged 18–50 years receiving 
E2V/DNG, 13 pregnancies occurred, six of which were 
attributed to method failure (unadjusted Pearl Index 0.73; 
adjusted Pearl Index 0.34). In the subgroup of women aged 
18–35 years, 12 pregnancies occurred, five of which were 
due to method failure (unadjusted Pearl Index 0.94; adjusted 
Pearl Index 0.40).
Safety
The main rationale for development of a combined oral con-
traceptive pill containing estradiol was based on the notion 
that a naturally occurring estrogen would be associated with 
fewer negative effects on lipid and glucose metabolism and 
hemostasis, and that adverse events would be minimized. In 
addition, a shorter half-life estrogenic component (estradiol) 
would possibly result in a lower rate of estrogen-associated 
complications, such as thromboembolic events, than those 
observed with the oral use of an estrogen (ethinyl estradiol) 
characterized by a longer half-life. The available literature 
suggests that the adverse events and metabolic effects of 
E2V/DNG are comparable with those of other combined oral 
contraceptive pills. Generally, adverse events in the reported 
studies were described as mild, and include headache, men-
strual abnormality, and breast discomfort, similar to that 
reported with more conventional combined oral contracep-
tive pill regimens.2,15 Also similar to other combined oral 
contraceptive pills, serious adverse events were uncommon 
among women participating in the E2V/DNG trials.2 Of note 
is that the currently published studies of E2V/DNG are too 
small to assess the frequency of venous thromboembolic 
events adequately, and other rare and uncommon adverse 
clinical outcomes in users of E2V/DNG. As such, while 
there is no current evidence to suggest an increased risk of 
thromboembolic events with E2V/DNG use compared with 
other estrogen-containing contraceptive methods, clinicians 
should consider the risk with this regimen to be similar to that 
of contraceptive regimens containing ethinyl estradiol and   
avoid using E2V/DNG in women who should not use estrogen-
containing contraceptives.
In the multicenter Phase III efficacy trial described 
above, 917 of 1377 (66%) participants reported one or more 
adverse events, with the vast majority of events being mild 
in nature. The most commonly reported adverse events 
included headache, diarrhea, and nasopharyngitis. Less com-
mon side effects, reported by 1%–3% of women, included 
breast pain and discomfort, acne, metrorrhagia, and weight 
gain. Serious adverse events were rare; those deemed pos-
sibly related to study medication included one case each of 
myocardial infarction, deep vein thrombosis, focal nodular 
hyperplasia of the liver, uterine leiomyoma, and ocular his-
toplasmosis syndrome. Again, this study was not powered 
to assess adequately the frequency of adverse events, such 
as thromboembolic events and other rare adverse events. 
Until further studies are done, clinicians should consider 
the safety profile with E2V/DNG to be similar to that of 
combined oral contraceptive pill regimens containing 35 µg 
ethinyl estradiol or less.
Despite the current lack of robust comparative epide-
miologic safety data, other studies have shown that the 
impact of E2V/DNG on lipid metabolism and hemostasis 
is apparently minimal. One open-label randomized study 
compared women on four-phasic E2V/DNG with those on 
triphasic ethinyl estradiol + levonorgestrel (ethinyl estradiol 
0.03 mg/levonorgestrel 0.05 mg for six days, ethinyl estra-
diol 0.04 mg/levonorgestrel 0.075 mg for five days, ethinyl 
estradiol 0.03 mg/levonorgestrel 0.125 mg for 10 days, 
then placebo for seven days).16 Healthy participants aged 
18–50 years were followed over seven cycles. Results sug-





  participants using E2V/DNG; high-density lipoprotein levels 
increased 7.9% ± 21.8% in E2V/DNG users, compared with 
a 2.3% ± 14.4% decrease in ethinyl estradiol/levonorgestrel 
users (P = 0.055). No significant differences in low-density 
lipoprotein levels, hemostatic characteristics, or carbohy-
drate metabolism were observed between the groups. Other 
studies measuring values for hemostasis parameters showed 
no clinically relevant change in most coagulation factors, 
including factors VII and VIII, antithrombin III, proteins C 
and S, or in activated protein C resistance and plasminogen 
activator inhibitor activity.5 Comparisons of D-dimer and 
fibrinogen levels among E2V/DNG and ethinyl estradiol/
levonorgestrel users demonstrated little or no negative 
impact with either combined oral contraceptive pill formula-
tion, with no clinically relevant differences between study 
groups.17 While these studies provide important information 
concerning the physiologic impact of E2V/DNG, they only 
provide information on a set of surrogate markers for which 
a clinical correlation with one or several adverse outcomes, 
including thromboembolic events, cannot and should not be 
made. Any consideration of a decreased or increased risk for 
thromboembolic events and other adverse outcomes must 
be directly determined by rigorous epidemiologic studies of 
E2V/DNG users.
These metabolic effects and their implications for 
clinical use have not been studied in women with medical 
  comorbidities. Of interest is use of E2V/DNG in women with 
diabetes, obesity, and other medical conditions. At this time, 
contraindications to use of E2V/DNG are the same as those 
for ethinyl estradiol-containing combined oral contracep-
tive pills, including pregnancy, uncontrolled hypertension, 
migraine with aura, acquired or inherited predisposition to 
arterial or venous thrombosis, coronary artery disease, breast 
cancer, heavy smoking, complicated valvular heart disease, 
severe hepatic disease including liver cancer, and history of   
current stroke or thromboembolism.
Bleeding profile
Historically, there was interest in creating a “natural” or 
endogenous estradiol-based combined oral contraceptive pill, 
but problems with breakthrough bleeding in the first several 
regimens evaluated demonstrated considerable user dissat-
isfaction and high discontinuation rates, thus preventing the 
introduction of any of these regimens. Pharmacokinetic and 
dose-ranging studies eventually led to the current marketed 
combination of E2V/DNG in a regimen that provides for 
contraceptive effectiveness in addition to a well tolerated 
bleeding profile.
In a multicenter, randomized, and double-blind trial,18 
804 women aged 18–50 years were randomized to either 
four-phasic E2V/DNG or monophasic ethinyl estradiol 
0.02 mg/levonorgestrel 0.1 mg in a standard 21/7 day regimen 
(ethinyl estradiol/levonorgestrel for 21 days, followed by placebo 
for seven days). In each of two 90-day reference periods, the 
mean number of bleeding and spotting days was less in the E2V/
DNG group than in the ethinyl estradiol/levonorgestrel group. 
In the first 90 days, the mean number was 17.3 ± 10.4 days 
for E2V/DNG users, and 21.5 ± 8.6 days for ethinyl estradiol/
levonorgestrel (P , 0.0001). In the second 90 days, the mean 
number was 13.4 ± 9.3 days and 15.9 ± 7.1 days, respectively 
(P , 0.0001). Scheduled withdrawal bleeding episodes were 
shorter and lighter in participants treated with E2V/DNG than 
in those treated with ethinyl estradiol/levonorgestrel, with 
a mean length of withdrawal bleeding of 4.1–4.7 days with 
E2V/DNG, compared with 5.0–5.2 with ethinyl estradiol/
levonorgestrel (P , 0.05 per cycle). In addition, the mean 
number of bleeding/spotting episodes was significantly less in 
the E2V/DNG group, with 3.7 ± 1.4 episodes, compared with 
4.1 ± 0.9 episodes in the ethinyl estradiol/levonorgestrel group 
(P , 0.0001) in the first reference period, and 3.0 ± 1.3 versus 
3.1 ± 0.9 episodes (P = 0.043) in the second reference period. 
However, it is important to note that the median numbers of 
bleeding episodes were identical between groups in both peri-
ods, in that there were 4.0 episodes in the first 90 days and 3.0 
episodes in the second 90 days, so the clinical relevance of the 
statistically significant findings is questionable. Furthermore, 
the clinical relevance of the fewer total number of bleeding/
spotting days is unclear. With regard to cycle control, most 
women in both groups experienced scheduled withdrawal 
bleeding, but the absence of scheduled withdrawal bleeding 
occurred more often in E2V/DNG users. The mean percentage 
of women on E2V/DNG who had an absent withdrawal bleed-
ing episode was 19.4% over seven cycles, compared with 7.7% 
of women using ethinyl   estradiol/levonorgestrel (P , 0.0001 
for each cycle), and most of these women experienced a single 
absent withdrawal bleeding   episode. An absence of any bleed-
ing, scheduled or unscheduled, occurred in 15.4% of cycles 
with E2V/DNG and 4.5% of cycles with ethinyl estradiol/
levonorgestrel. Rates of intermenstrual bleeding were similar 
between groups; approximately 14% and 12% of E2V/DNG 
and ethinyl estradiol/levonorgestrel users, respectively, experi-
enced such bleeding. Typically the bleeding was reported to be 
light, and occurred most commonly during the first treatment 
cycle. Patient satisfaction in the two groups was similar, with 
most participants (79%) reporting being satisfied with their 
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Patient satisfaction
Consistent and correct use of prescribed contraceptive meth-
ods depends on several different and unrelated factors, but 
satisfaction with a chosen method is a major determinant of 
successful and ongoing use.19 As described above, use of 
E2V/DNG is generally well tolerated. In the large Phase III 
efficacy trial,3 140 of 1377 participants (10.2%) discontinued 
the study medication due to adverse events, with menstrual 
irregularity (1.7%), acne (1.0%), and weight gain (0.9%) 
being the most commonly cited reasons for discontinuation. 
In the trial comparing bleeding profiles and cycle control with 
E2V/DNG and ethinyl estradiol/levonorgestrel,18 a subjective 
assessment of satisfaction was obtained. Participants were 
queried regarding their satisfaction with treatment and asked 
to rate their level of satisfaction according to five categories, 
ie, very satisfied, somewhat satisfied, neither satisfied nor 
dissatisfied, dissatisfied, or very dissatisfied. Most women 
in both groups reported that they were somewhat satisfied 
or very satisfied with treatment (79.4% in the E2V/DNG 
group, 79.9% in the ethinyl estradiol/levonorgestrel group). 
Over one third of women in both groups rated themselves as 
very satisfied with treatment (39.8% in the E2V/DNG group, 
35.3% in the ethinyl estradiol/levonorgestrel group).
Noncontraceptive benefits
Aside from providing reliable pregnancy prevention, com-
bined oral contraceptive pills offer certain gynecologic and 
nongynecologic health benefits. These noncontraceptive 
benefits include menstrual cycle control, decreased menstrual 
blood loss, reduced dysmenorrhea, prevention of ovarian 
cyst formation, decreased ectopic pregnancy risk, protection 
against endometrial, ovarian and colon cancer, decreased risk 
of pelvic inflammatory disease, less benign breast disease, 
treatment of acne, and increased bone mass.20
Specifically, heavy menstrual bleeding (previously 
described as “menorrhagia”) is a common indication for 
prescription of the combined oral contraceptive pill, and 
E2V/DNG has been shown to treat heavy menstrual bleed-
ing effectively. Two randomized, placebo-controlled studies 
have assessed the effects of E2V/DNG on heavy menstrual 
bleeding. In the first trial, 190 women with heavy or pro-
longed menstrual bleeding were randomized in a 2:1 fashion 
to E2V/DNG and placebo. Participants using E2V/DNG 
experienced significantly higher response rates than those on 
placebo (43.75% versus 4.17%, P , 0.0001). Quantitative 
measurement of menstrual blood loss showed that E2V/DNG 
users experienced greater reductions in blood loss compared 
with placebo (−353.1 versus −130.4 mL, P , 0.0001). 
  Correspondingly, hemoglobin, hematocrit, and ferritin levels 
in E2V/DNG users were significantly improved. Efficacy for 
treatment of heavy and/or prolonged bleeding was similarly 
demonstrated in the second trial,21 in which participants 
receiving E2V/DNG experienced significantly less men-
strual blood loss than those using placebo (adjusted mean 
difference −373 mL, 95% confidence interval −490, −255; 
P , 0.0001). Increased hemoglobin and ferritin concentra-
tions were similarly found in this trial. These trials provide 
compelling evidence that E2V/DNG offers effective treat-
ment for heavy menstrual bleeding.
Despite the lack of a study directly comparing the effects 
of E2V/DNG and an ethinyl estradiol-containing combined 
oral contraceptive pill on heavy menstrual bleeding, the 
aforementioned trials were used by European Union regula-
tors to endorse the indication of E2V/DNG for the treatment 
of heavy menstrual bleeding in women without organic 
pathology who choose to use an oral contraceptive. In the US, 
the E2V/DNG regimen is indicated solely for the prevention 
of pregnancy. Additional study is needed to evaluate the clini-
cal advantages of E2V/DNG over traditional   formulations. 
Direct comparison of magnitude of reduced menstrual blood 
loss in women with menorrhagia is required, because it is 
well documented that ethinyl estradiol-containing pills con-
fer such an effect.7,8 Furthermore, issues of cost and access 
must be considered when appraising a new medication. The 
potential clinical benefits of E2V/DNG use must take into 
account its relative expense and, in turn, restricted avail-
ability, especially in resource-poor settings.
Conclusion
The new combined E2V/DNG oral contraceptive pill regimen 
offers reliable contraceptive efficacy, similar to that observed 
and expected with all combined oral contraceptive pills. 
Effects on carbohydrate and lipid metabolism and hemosta-
sis factors are most likely minimal and not likely to affect 
women in a healthy population of users adversely. Menstrual 
cycle control and bleeding profiles have been reported to be 
well accepted by study participants, and most users in trials 
report satisfaction with the method. Frequency and type of 
adverse events are similar to those reported by users of ethinyl 
estradiol-containing combined oral contraceptive pills, and 
are not typically severe. However, current evidence supports 
the premise that the safety profile of E2V/DNG is similar 
to that of low-dose combined oral contraceptive pills that 
contain ethinyl estradiol, and thus it should not be provided 
to women in whom estrogen-containing contraceptive use 
is contraindicated.International Journal of Women’s Health
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E2V/DNG has also been demonstrated to be effective for 
the treatment of heavy menstrual bleeding in women choos-
ing to use the regimen to prevent pregnancy. Despite data 
demonstrating similar cycle control between E2V/DNG and 
older formulations, the current literature lacks comparative 
trials of E2V/DNG and ethinyl estradiol-containing pills 
with regard to heavy menstrual bleeding. As with any new 
combined oral contraceptive pill formulation, additional and 
more extensive data regarding safety, effectiveness, and side 
effects will need to be elicited from its ongoing use. None-
theless, the current evidence supports the use of E2V/DNG 
as a first-line, mainstream oral contraceptive option for 
women seeking effective, reversible, and well tolerated oral 
contraception.
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